Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | GFER | P55789 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GHSR | Q92847 | 11/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14083542 | 0.88 | TRPV1 (0.70) | TRPV1MAPTGFERNPSR1LMNA | |
| SCHEMBL14083999 | 0.85 | TRPV1 (0.59) | TRPV1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL14083056 | 0.85 | TRPV1 (0.58) | TRPV1MAPTLMNAALDH1A1CYP2C19 | |
| SCHEMBL14084033 | 0.84 | NPC1 (0.61) | TRPV1MAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL14083912 | 0.83 | TRPV1 (0.56) | TRPV1ALDH1A1 | |
| SCHEMBL14083929 | 0.83 | TRPV1 (0.60) | TRPV1MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL14083985 | 0.83 | NPC1 (0.59) | TRPV1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14084017 | 0.83 | MAPT (0.52) | TRPV1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL14083932 | 0.83 | NPC1 (0.57) | TRPV1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL14084036 | 0.83 | RAB9A (0.55) | TRPV1MAPTNPSR1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885MAPT 2822/4885GFER 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.